A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This phase 3, 26-week, randomized, double-blind, placebo-controlled, multi-center study will
evaluate the safety and efficacy of one dose of Tenapanor in subjects with
constipation-predominant irritable bowel syndrome (IBS-C) as defined by the ROME III criteria
and who have active disease as determined after a two-week screening period. Subjects who
qualify and are randomized into the study will either receive 50mg BID of Tenapanor (1:1) for
a 26 week treatment period.